Trial Profile
Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy: A Prospective Randomized Multicenter Study
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 20 Sep 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 17 Sep 2019 Status changed from not yet recruiting to discontinued.
- 18 Jul 2016 New trial record